Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 6/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL449243 | 1.00 | TSHR (0.44) | TSHRTHRBSPHK1DNM1OPRM1 | |
| SCHEMBL127233 | 1.00 | TSHR (0.44) | TSHRTHRBSPHK1DNM1OPRM1 | |
| Fluoride SCHEMBL27854332 | 0.97 | TSHR (0.42) | TSHRTHRBSPHK1DNM1OPRM1 | |
| SCHEMBL2729272 | 0.97 | TSHR (0.39) | TSHRTHRBSPHK1DNM1OPRM1 | |
| SCHEMBL475837 | 0.88 | TSHR (0.35) | TSHRTHRBSPHK1OPRM1LMNA | |
| SCHEMBL15914828 | 0.79 | TSHR (0.40) | TSHRTHRBSPHK1DNM1OPRM1 | |
| SCHEMBL1557239 | 0.78 | TSHR (0.44) | TSHRTHRBDNM1OPRM1TRPM8 | |
| SCHEMBL15916644 | 0.78 | TSHR (0.44) | TSHRTHRBDNM1OPRM1TRPM8 | |
| Decane SCHEMBL28143340 | 0.71 | TSHR (0.73) | TSHRTHRBDNM1OPRM1ALDH1A1 | |
| Isobutane SCHEMBL28169778 | 0.71 | TSHR (0.73) | TSHRTHRBDNM1OPRM1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118439914-A | Preparation method and application of deuterated irinotecan and intermediate thereof | 博瑞生物医药（苏州）股份有限公司 | 2024-08-06 | — | — | CN | claimed |
| US-20170283368-A1 | METHODS FOR SYNTHESIZING SUBSTITUTED TETRACYCLINE COMPOUNDS | PARATEK PHARMACEUTICALS, INC. | 2017-10-05 | — | — | US | claimed |
| EP-2014797-A2 | Coating composition for interconnection part of electrode and plasma display panel including the same | Samsung SDI Co., Ltd. (KR) | 2009-01-14 | — | — | EP | claimed |
| US-20080303439-A1 | Coating composition for interconnection part of electrode and plasma display panel including the same | SAMSUNG SDI CO., LTD., A CORP. OF THE REPUBLIC OF KOREA (KR) | 2008-12-11 | — | — | US | claimed |
| US-20250340507-A1 | METHODS FOR SYNTHESIZING SUBSTITUTED TETRACYCLINE COMPOUNDS | PARATEK PHARM INNC (US) | 2025-11-06 | — | — | US | disclosed |
| CN-118439914-A | Preparation method and application of deuterated irinotecan and intermediate thereof | 博瑞生物医药（苏州）股份有限公司 | 2024-08-06 | — | — | CN | disclosed |
| EP-4234643-A2 | ANTIFOULING COMPOSITION | Jotun A/S (NO) | 2023-08-30 | — | — | EP | disclosed |
| CN-108070055-B | Antifouling composition | 佐敦公司 | 2022-10-04 | — | — | CN | disclosed |
| CN-108070054-B | Anti-fouling composition | 佐敦公司 | 2022-05-03 | — | — | CN | disclosed |
| CN-109983083-B | Antifouling composition | 佐敦有限公司 | 2021-08-17 | — | — | CN | disclosed |
| CN-106047173-B | Antifouling composition | 佐敦集团 | 2020-12-11 | — | — | CN | disclosed |
| CN-106146851-B | Photocurable composition and cured product containing same | 信越化学工业株式会社 | 2020-10-23 | — | — | CN | disclosed |
| EP-1448568-A2 | DICOPS CONTAINING ACETYLENIC SUBSTITUENTS | ExxonMobil Chemical Patents Inc. (US) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003040070-A2 | DICOPS CONTAINING ACETYLENIC SUBSTITUENTS | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2003-05-15 | — | — | WO | disclosed |
| EP-1257531-A2 | METHOD FOR THE PREPARATION OF CARBOTHIOIC ACIDS | Abbott Laboratories (US) | 2002-11-20 | — | — | EP | disclosed |
| US-20020133032-A1 | Method for the preparation of fluticasone and related 17beta-carbothioic esters using a novel carbothioic acid synthesis and novel purification methods | ABBOTT LABORATORIES | 2002-09-19 | — | — | US | disclosed |
| WO-2001062722-A2 | METHOD FOR THE PREPARATION OF FLUTICASONE AND RELATED 17BETA-CARBOTHIOIC ESTERS USING A NOVEL CARBOTHIOIC ACID SYNTHESIS AND NOVEL PURIFICATION METHODS | ABBOTT LABORATORIES (US) | 2001-08-30 | — | — | WO | disclosed |
| WO-1996036726-A1 | BIOCONVERSION OF BETA KETO-ESTER TO (R) HYDROXYESTER | MERCK & CO., INC. (US) | 1996-11-21 | — | — | WO | disclosed |
| US-5534422-A | Bioconversion of beta keto-ester to (R) hydroxyester | MERCK & CO., INC. (US) | 1996-07-09 | — | — | US | disclosed |
| US-5294737-A | Hydrolysis, cyclization, condensation | THE RESEARCH FOUNDATION STATE UNIVERSITY OF NEW YORK (US) | 1994-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020133032-A1 | Method for the preparation of fluticasone and related 17beta-carbothioic esters using a novel carbothioic acid synthesis and novel purification methods | HSD17B7, CYP17A1, NR5A1 | TSHR 212/4885THRB 288/4885SPHK1 2530/4885 |
| US-20250340507-A1 | METHODS FOR SYNTHESIZING SUBSTITUTED TETRACYCLINE COMPOUNDS | TET3, TET1, DHFR | TSHR 2369/4885THRB 1828/4885SPHK1 3011/4885 |
| US-20170283368-A1 | METHODS FOR SYNTHESIZING SUBSTITUTED TETRACYCLINE COMPOUNDS | TET3, TET1, DHFR | TSHR 2369/4885THRB 1828/4885SPHK1 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.